U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H19F2N5O2
Molecular Weight 399.394
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIMODIVIR

SMILES

OC(=O)[C@H]1C2CCC(CC2)[C@@H]1NC3=NC(=NC=C3F)C4=CNC5=NC=C(F)C=C45

InChI

InChIKey=JGPXDNKSIXAZEQ-SBBZOCNPSA-N
InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H19F2N5O2
Molecular Weight 399.394
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

JNJ-872 is an inhibitor of influenza virus replication that offers a potential for the treatment of pandemic and seasonal influenza.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P03427
Gene ID: NA
Gene Symbol: PB2
Target Organism: Influenza A virus (strain A/Wilson-Smith/1933 H1N1) (Influenza A virus|||(strain A/WS/1933 H1N1))
0.32 nM [EC50]
1.6 µM [Ki]
PubMed

PubMed

TitleDatePubMed
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
2014 Aug 14
JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses.
2016 Sep
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.
2017 Feb 9
Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
2018
Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
2018 Nov
Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
2019 Mar 15
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:41:58 GMT 2023
Edited
by admin
on Fri Dec 15 16:41:58 GMT 2023
Record UNII
DFC121MXC3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIMODIVIR
INN   WHO-DD  
INN  
Official Name English
JNJ-63623872-ZCD
Code English
JNJ872
Code English
VX-787 ANHYDROUS BASE
Common Name English
pimodivir [INN]
Common Name English
JNJ-63623872
Code English
(2S,3S)-3-((5-FLUORO-2-(5-FLUORO-1H-PYRROLO(2,3-B)PYRIDIN- 3-YL)PYRIMIDIN-4-YL)AMINO)BICYCLO(2.2.2)OCTANE-2-CARBOXYLIC ACID
Systematic Name English
Pimodivir [WHO-DD]
Common Name English
VX-787
Code English
JNJ-872
Code English
BICYCLO(2.2.2)OCTANE-2-CARBOXYLIC ACID, 3-((5-FLUORO-2-(5-FLUORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-4-PYRIMIDINYL)AMINO)-, (2S,3S)-
Systematic Name English
JNJ63623872
Code English
(2S,3S)-3-(5-FLUORO-2-(5-FLUORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YLAMINO)BICYCLO(2.2.2)OCTANE-2-CARBOXYLIC ACID
Systematic Name English
PIMODIVIR [USAN]
Common Name English
Code System Code Type Description
FDA UNII
DFC121MXC3
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
NCI_THESAURUS
C158086
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
SMS_ID
100000174647
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
WIKIPEDIA
Pimodivir
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
NCI_THESAURUS
C170320
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
ALTERNATIVE
INN
10321
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
PUBCHEM
67286591
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
USAN
EF-35
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
DRUG BANK
DB14974
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
EPA CompTox
DTXSID801028095
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
CAS
1629869-44-8
Created by admin on Fri Dec 15 16:41:58 GMT 2023 , Edited by admin on Fri Dec 15 16:41:58 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Originator: Vertex Pharmaceuticals; Developer: Janssen Pharmaceuticals, Vertex Pharmaceuticals; Class: Antiviral; Mechanism of Action: Viral protein inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase II for Influenza A virus infections; Most Recent Events: 01 Jun 2016 Janssen Research and Development completes a pharmacokinetics phase I trial in Healthy volunteers in USA and Belgium (PO) (NCT02652650), 01 Apr 2016 Janssen Research and Development completes a bioavailability phase I trial in Healthy volunteers in Belgium (PO) (NCT02659735), 01 Apr 2016 Janssen Research & Development completes a phase I trial in Healthy volunteers in Belgium (NCT02658825)